The evolving landscape of immune-mediated glomerular diseases

Over the past year, trial data have emerged on therapeutic interventions in IgA nephropathy and lupus nephritis, including the effects of different doses of glucocorticoids and several novel targeted therapies. These data, in combination with the discovery of autoantibodies targeting nephrin in minimal change disease, can inform the management of immune-mediated glomerular diseases.

Automated summary

Trial data on therapeutic interventions in IgA nephropathy and lupus nephritis, along with the discovery of autoantibodies targeting nephrin in minimal change disease, can provide guidance for the management of immune-mediated glomerular diseases.